1800-272-662
Shopping Cart 0
countryflagAU
Login

Emyria Ltd

Healthcare AU EMD

0.044AUD
-0.002(4.35%)

Last update at 2026-03-13T04:33:00Z

Day Range

0.040.04
LowHigh

52 Week Range

0.020.08
LowHigh

Fundamentals

  • Previous Close 0.05
  • Market Cap35.49M
  • Volume608674
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.80385M
  • Revenue TTM2.29M
  • Revenue Per Share TTM0.004
  • Gross Profit TTM 0.46M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -3.14276M -13.98307M -5.13112M -7.32769M -4.90623M
Minority interest - - - - -
Net income -3.14276M -11.45575M -5.13112M -7.32769M -4.90623M
Selling general administrative 3.52M 3.43M 3.43M 4.61M 1.95M
Selling and marketing expenses - 1.62M - - -
Gross profit 0.02M -0.16755M -0.64751M -0.99506M -1.05673M
Reconciled depreciation - 0.69M 0.40M 0.39M 0.34M
Ebit -2.49380M -13.72976M -4.88102M -7.25547M -4.83938M
Ebitda -2.39289M -13.03485M -4.48042M -6.86546M -4.49451M
Depreciation and amortization 0.10M 0.69M 0.40M 0.39M 0.34M
Non operating income net other - - - - -
Operating income -2.64524M -6.90268M -4.24330M -6.85015M -3.42784M
Other operating expenses 4.04M 9.11M 2.15M 4.40M 2.29M
Interest expense 0.13M 0.25M 0.13M 0.07M 0.07M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income - 0.02M 0.03M 0.01M 0.02M
Net interest income - -0.23174M -0.09846M -0.05951M -0.04370M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -2.52732M 2.34M 1.81M 1.68M
Total revenue 1.39M 2.20M 1.59M 1.35M 1.21M
Total operating expenses 2.67M 6.74M 6.48M 8.01M 5.42M
Cost of revenue 1.37M 2.37M 2.24M 2.35M 2.26M
Total other income expense net -0.49752M -7.08039M 2.09M 1.74M 1.62M
Discontinued operations - - - - -
Net income from continuing ops - -11.45575M -5.13112M -7.32769M -4.90623M
Net income applicable to common shares -3.14276M -11.45575M -5.13112M -7.32769M -4.90623M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 6.62M 5.43M 10.16M 8.25M 9.06M
Intangible assets 0.00085M - 6.67M 2.89M 0.73M
Earning assets - - - - -
Other current assets 0.22M 0.33M 0.05M 0.15M 0.08M
Total liab 1.31M 3.00M 3.37M 1.93M 1.88M
Total stockholder equity 5.31M 2.43M 6.79M 6.32M 7.18M
Deferred long term liab - - - - -
Other current liab 0.30M 0.71M 2.03M 0.84M 0.88M
Common stock 41.89M 36.26M 29.80M 24.64M 19.31M
Capital stock - - 29.80M 24.64M 19.31M
Retained earnings -38.03665M -35.35031M -25.41814M -20.28702M -12.95933M
Other liab - - 0.08M 0.11M 0.10M
Good will 1.56M 1.56M - - -
Other assets - - 0.14M 0.16M 0.16M
Cash 3.57M 1.57M 2.73M 3.88M 6.53M
Cash and equivalents - - - - -
Total current liabilities 0.80M 2.24M 3.15M 1.46M 1.03M
Current deferred revenue - 0.00000M -1.83743M -0.26889M -0.29410M
Net debt -2.95655M 0.15M -1.46240M -3.24677M -5.57923M
Short term debt 0.13M 1.03M 1.13M 0.27M 0.20M
Short long term debt - - 0.91M - -
Short long term debt total 0.61M 1.72M 1.27M 0.63M 0.95M
Other stockholder equity - - -4.38577M -4.35029M -6.35147M
Property plant equipment - - 0.50M 1.08M 1.28M
Total current assets 3.81M 1.93M 2.85M 4.12M 6.88M
Long term investments - - - - -
Net tangible assets - - 0.12M 3.43M 6.44M
Short term investments - - - - -
Net receivables 0.02M 0.03M 0.09M 0.09M 0.27M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.37M 0.50M 1.83M 0.62M 0.25M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.45M 1.51M 2.41M 1.97M 0.83M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.38M 0.52M 0.14M 0.16M 0.16M
Deferred long term asset charges - - - - -
Non current assets total 2.81M 3.50M 7.31M 4.13M 2.18M
Capital lease obligations - - 0.36M 0.63M 0.95M
Long term debt total - - 0.14M 0.36M 0.75M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -1.37771M -3.23372M -2.02919M -0.66139M
Change to liabilities - - 0.42M 0.06M 0.25M
Total cashflows from investing activities 0.08M -1.37771M -3.23372M -2.02919M -0.66139M
Net borrowings - -0.27985M 0.66M -0.23270M -0.42589M
Total cash from financing activities 4.63M 4.50M 5.84M 4.81M 7.44M
Change to operating activities - - 0.11M 0.05M 0.04M
Net income -3.14276M -11.45575M -5.13112M -7.32769M -4.90623M
Change in cash 2.00M -1.16732M -1.14594M -2.64946M 2.84M
Begin period cash flow 1.57M 2.73M 3.88M 6.53M 3.69M
End period cash flow 3.57M 1.57M 2.73M 3.88M 6.53M
Total cash from operating activities -2.70468M -4.28477M -3.77156M -5.42782M -3.93732M
Issuance of capital stock - 5.16M 5.50M 5.04M 8.40M
Depreciation 0.47M 0.69M 0.32M 0.31M 0.28M
Other cashflows from investing activities 0.09M -1.07912M -3.21690M 0.00000M -0.65333M
Dividends paid - - - 0.77M -
Change to inventory - - - - -
Change to account receivables -0.00718M 0.05M 0.00200M 0.08M -0.20196M
Sale purchase of stock 5.73M -0.13936M 5.50M -0.52750M -0.52750M
Other cashflows from financing activities -0.81368M -0.27985M 1.14M 1.30M -0.19098M
Change to netincome - - 0.43M 1.32M 0.54M
Capital expenditures 0.01M 0.16M 3.23M 2.03M 0.66M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.00274M -0.28027M 0.00200M 0.08M -0.20196M
Stock based compensation 0.41M 0.36M 0.42M 1.43M 0.43M
Other non cash items -0.43162M 6.40M 1.04M 1.59M 0.69M
Free cash flow -2.71857M -4.44387M -7.00528M -7.45701M -4.59870M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EMD
Emyria Ltd		 -0.002 4.35% 0.04 - - 15.49 3.07 12.31 -7.1543
PME
Pro Medicus Ltd		 -0.55 0.41% 133.00 59.62 73.53 58.00 36.74 58.50 75.61
AYA
ARTRYA Ltd		 -0.17 5.04% 3.20 - - 17488.26 5.98 5516.69 0.33
EIQ
Echoiq Ltd		 0.02 2.94% 0.70 - - 5046.68 25.81 4779.15 -8.2701
CGS
Cogstate Ltd		 -0.02 0.92% 2.15 23.89 19.96 6.58 5.14 4.32 13.45

Reports Covered

Stock Research & News

View All

Profile

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Leederville, Australia.

Emyria Ltd

D2, 661 Newcastle Street, Leederville, WA, Australia, 6007

Key Executives

Name Title Year Born
Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D. Exec. Chairman 1970
Dr. Michael Winlo MD & Director NA
Dr. Alistair Vickery Exec. Medical Director & Director NA
Dr. Karen L. Smith L.L.M, L.L.M., M.B.A., M.D., PH.D. Exec. Director & Chairman of Strategic Advisory Board 1968
Mr. Joseph Daniel Ohayon ACA, MBA Intl Bus. Chief Financial Officer NA
Ms. Tracie Ernenwein Head of Research & Drug Devel. NA
Mary-Ann Rennie Head of Corp. Operations NA
Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA Company Sec. NA
Mary-Ann Rennie Head of Corporate Operations NA
Dr. Alistair Vickery Executive Medical Director & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.